Medicare Enrolled

Dr. Alexandra Gillespie, MD

Cytopathology Physician · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
5327 N CENTRAL EXPY, Dallas, TX 75205
2142195880
In practice since 2006 (19 years)
NPI: 1154345841 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gillespie from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gillespie? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gillespie

Dr. Alexandra Gillespie is a cytopathology physician in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Gillespie performed 15,989 Medicare services across 12,328 unique beneficiaries.

Between the years covered by Open Payments, Dr. Gillespie received a total of $261 from 4 pharmaceutical and/or device companies across 5 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cytopathology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gillespie is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 3% volume in TX$ $261 industry payments

Medicare Practice Summary

Medicare Utilization ↗
15,989
Medicare services
Top 3% in TX for cytopathology physician
12,328
Unique beneficiaries
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~842 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Pap test, automated thin layer preparation; automated system and manual rescreening3,376$26$60
Infectious disease DNA/RNA test2,297$34$65
Detection test by nucleic acid for human papillomavirus (hpv), high-risk types1,776$34$65
Yeast/candida DNA test1,257$34$65
Pap test1,090$15$58
Detection test for gardnerella vaginalis (bacteria), amplified probe technique784$34$65
Tissue pathology examination, moderate complexity651$54$125
Urine culture, bacterial colony count576$8$40
Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique444$34$65
Special stained specimen slides to examine tissue including interpretation and report256$65$115
Comprehensive metabolic blood panel250$10$50
Complete blood count (CBC), automated235$6$35
Bacterial culture, aerobic191$8$40
Antibiotic sensitivity test183$8$65
Testosterone (hormone) level, total171$25$65
Microscopic genetic analysis of tumor, manual166$95$195
Measurement of total estradiol (hormone)158$27$71
Cell examination of specimen, selective cellular enhancement technique135$50$120
Vitamin D level test129$29$73
Thyroid stimulating hormone (TSH) test119$16$43
Tissue staining for diagnosis, initial119$79$160
Gonadotropin, follicle stimulating (reproductive hormone) level109$18$47
Pap test, manual screening109$20$90
Sex hormone binding globulin (protein) level99$21$55
Detection of mycoplasma genitalium by dna or rna probe96$34$75
Special stained specimen slides to identify organisms including interpretation and report91$86$150
Detection test by nucleic acid for human papillomavirus (hpv), types 16 and 18 only90$39$180
Detection test for candida species (yeast), direct probe technique81$20$38
Detection test for gardnerella vaginalis (bacteria), direct probe technique81$20$38
Detection test by nucleic acid for trichomonas vaginalis (genital parasite), direct probe technique81$20$38
Automated urinalysis79$2$11
Thyroid hormone, t3 measurement, free78$17$43
Lipid panel (cholesterol and triglycerides)66$13$44
Detection test by nucleic acid for herpes simplex virus, amplified probe technique63$34$75
Free thyroxine (T4) test62$9$24
Microsomal antibodies (autoantibody) measurement51$14$20
Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique47$33$68
Progesterone (reproductive hormone) level46$20$59
Detection test by immunoassay technique for escherichia coli 0157 (e. coli)44$12$22
Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique44$34$73
Hemoglobin A1c test (diabetes monitoring)32$10$25
Immunologic analysis for detection of tumor antigen, quantitative; ca 12526$20$53
Basic metabolic blood panel21$8$22
Thyroglobulin (thyroid protein) antibody measurement20$16$40
Ferritin level test (iron stores)19$13$35
Urine culture, bacterial identification19$8$20
Iron level test17$6$17
Detection test by immunoassay technique for hiv-1 antigen and hiv-1 and hiv-2 antibodies17$24$62
Transferrin (iron binding protein) level15$12$32
Vitamin B-12 level test12$15$38
Hepatitis c antibody measurement11$13$36
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$261
Total received (2019-2024)
Avg $65/year across 4 years
Top 26% in TX for cytopathology physician
4
Companies
5
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$261 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$201
2022
$13
2020
$26
2019
$21

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Endologix LLC
$131
Hologic Sales and Service, LLC
$70
Roche Diagnostics Corporation
$47
Smith+Nephew, Inc.
$13
Top 3 companies account for 94.9% of total payments
Associated products mentioned in payments ›
RENASYS TOUCH · TD BenchMark IHC/ISH and Special Stains Reagents · TD VENTANA Primary Staining Instruments and Reagents · THINPREP 2000 PROCESSOR
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $2 per 100 Medicare services performed
Looking for a cytopathology physician in Dallas?
Compare cytopathology physicians in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse cytopathology physicians nearby

Geographic Context

Cytopathology Physicians within 10 mi
24
Per 100K population
0.9
County median income
$74,149
Nearest hospital
TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN
2.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Gillespie is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Gillespie experienced with pap test, automated thin layer preparation; automated system and manual rescreening?
Based on Medicare claims data, Dr. Gillespie performed 3,376 pap test, automated thin layer preparation; automated system and manual rescreening services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gillespie receive payments from pharmaceutical companies?
Yes. Dr. Gillespie received a total of $261 from 4 companies across 5 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gillespie's costs compare to other cytopathology physicians in Dallas?
Dr. Gillespie's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gillespie) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →